Our non-governmental organization conduct community service projects that help patients with diseases neglected by industrial research and development (R&D).

Our mission is to address the imbalance in access to primary care and medicines on a global scale. We do this in several ways:

  1. We promote, initiate and carry out projects that enable and improve the economical treatment of patients with neglected diseases (specifically cutaneous leishmaniasis CL) in European bio-research and medical product development.
  2. As a non-profit institution with limited resources, we are taking the first development steps in close contact with the regulatory authorities to make the product available to patients as quickly as possible, even if only temporarily. In order to achieve CE certification and thus final market access, we hope to find financially stronger industrial partners.
  3. We sensitize European policymakers to the idea that the right to education and self-supporting work is a human right to equality in access to basic health care. They should understand that this human right is crucial for human dignity and for the establishment of social cohesion and peace in communities. This right is set out in Articles 11 (The right to health protection) and 13 (The right to social and medical support) of the 1996 European Social Charter.
  4. We help foreign doctors qualify as doctoral students at European universities. Our experience has shown us that our personal investment in the careers of these young academics has motivated them to act as multipliers of German-Swiss research opportunities upon their return to their home countries. However, there are also countries abroad to which such a return to their home country is currently not possible for political reasons. So we help them as much as possible with their integration into the EU. Foreign students have repeatedly used our connections, particularly in the departments of Pharmacy and Chemistry, to write final theses (Bachelor/Master) on the subject area (Syria, Iran, Turkey).
  5. Since 2022, 2 surgical specialists from Spain and Afghanistan have been working in a large group practice on doctorates on the use of LeiProtect for chronic wounds of various origins (including varicose and diabetic ulcers).